RaQualia Pharma Inc.
4579.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.02B
Close$
Share Statistics
| Market cap | $15.02 Billion |
|---|---|
| Enterprise Value | $13.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $11.53 |
| Beta | 0.88 |
| Outstanding Shares | 26,019,400 |
Return
| Return on Equity | 2.06% |
|---|---|
| Return on Assets | 1.46% |
| Return on Invested Capital | 3.72% |
Valuation & Multiples
| P/E Ratio | 68.6 |
|---|---|
| PEG | -220.84 |
| Price to Sales | 4.12 |
| Price to Book Ratio | 2.05 |
| Enterprise Value to Revenue | 3.39 |
| Enterprise Value to EBIT | 35.74 |
| Enterprise Value to Net Income | 82 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About RaQualia Pharma Inc.
85 employees
CEO: Masaki Sudo RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidat...